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Inhibition of Zika virus replication
by G-quadruplex-binding ligands
Prativa Majee,1 Aryamav Pattnaik,2 Bikash R. Sahoo,2 Uma Shankar,1 Asit K. Pattnaik,2 Amit Kumar,1
and Debasis Nayak1
1Discipline

of Biosciences and Biomedical Engineering, Indian Institute of Technology Indore, Madhya Pradesh 453552, India; 2School of Veterinary Medicine and

Biomedical Sciences and Nebraska Center for Virology, University of Nebraska-Lincoln, Lincoln, NE 68583, USA

Zika virus (ZIKV), a mosquito-transmitted Flavivirus, emerged
in the last decade causing serious diseases and affecting human
health globally. Currently, no licensed vaccines or antivirals are
available to combat ZIKV, although several vaccine candidates
are in the pipeline. In recent years, the presence of non-canonical G-quadruplex (GQ) secondary structures in viral genomes
has ignited signiﬁcant attention as potential targets for antiviral strategy. In this study, we identiﬁed several novel
conserved potential GQ structures by analyzing published
ZIKV genome sequences using an in-house algorithm. Biophysical and biochemical analysis of the RNA sequences containing these potential GQ sequences suggested the existence
of such structures in the ZIKV genomes. Studies with known
GQ structure-binding and -stabilizing ligands such as Braco19 and TMPyP4 provided support for this contention. The
presence of these ligands in cell culture media led to signiﬁcant
inhibition of infectious ZIKV yield, as well as reduced viral
genome replication and viral protein production. Overall,
our results, for the ﬁrst time, show that ZIKV replication can
be inhibited by GQ structure-binding and -stabilizing compounds and suggest a new strategy against ZIKV infection mitigation and control.

INTRODUCTION
The emergence of the Zika virus (ZIKV) is of great concern worldwide in recent times. Though the virus was ﬁrst isolated in 1947 in
the Zika forest of Uganda,1 it came to prominence mainly after the
2007 outbreak for its association with serious congenital and neurological abnormalities.2–5 The outbreaks, which occurred sporadically
in parts of African and Asian countries, later manifested into major
outbreaks in the Island of Yap, Federated States of Micronesia6 in
2007, French Polynesia7 in 2013, and the most explosive outbreak
in Brazil8,9 in 2015. It is estimated that over 86 countries across the
world have now witnessed ZIKV infections. The ZIKV infection
may be asymptomatic or manifest as mild, self-limiting, ﬂu-like
febrile illnesses that are resolved within days. In certain cases, it can
even give rise to congenital abnormalities and severe complications
in children, including microcephaly, hydrocephaly, cerebral atrophy,
ventriculomegaly, cortical malformations, intracranial calciﬁcations,
etc.2–5,10 In adults, ZIKV infection may lead to fatal conditions
involving neurological complications like acute auto-immune-medi-

ated damage to peripheral nerves (Guillain-Barré syndrome), neuropathy, myelitis, meningoencephalitis, ischemic infarction, seizures,
vasculopathy, etc.11,12
ZIKV, along with other mosquito-borne viruses like dengue virus
(DENV), West-Nile virus (WNV), and Yellow fever virus (YFV), belongs to the Flaviviridae family. This enveloped virion consists of a
positive-sense single-stranded RNA genome that codes for a single
polyprotein that is further processed into three structural (capsid
[C], precursor membrane [prM], and envelope [E] protein) and seven
non-structural (NS) proteins (NS1, NS2A, NS2B, NS3, NS4A, NS4B,
and NS5).13 As there is no effective licensed vaccine or drug currently
available, various strategies and approaches are being explored for the
discovery of antiviral drugs against ZIKV. These include targeting
viral proteins (structural and NS), repurposing the already approved
drugs, etc.,14 and therefore further research on alternate strategies for
the discovery of new and effective antiviral compounds is warranted.
The G-quadruplex (GQ)-forming sequences are being explored
extensively as potential drug targets and have gained signiﬁcant attention as potential antiviral strategies in recent years.15,16 The stretches
of guanines in DNA or RNA sequences self-assemble to form a noncanonical secondary structure that can provide a specialized binding
pocket for planar ligands.17 Targeting GQ structures for cancer treatment are being explored continuously for a very long time as they are
reported to be extensively found in the telomeric region of the human
chromosome.18 They are subsequently present in the promoter region
of several proto-oncogenes like Bcl2 (B cell lymphoma 2)19 and c-Myc
(cancer myelocytomatosis).20 Promisingly, researchers have designed
ligands, which can speciﬁcally target these GQ sequences and inhibit
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by the investigators. In this study, we have discovered a number of
additional GQ-structure-forming sequences that are exclusively
conserved in the ZIKV genome in addition to those reported by
Fleming et al.31 Taking ZIKV genomic RNA sequences carrying
several of these potential GQ structures, and by using various assays
such as ﬂuorescence titration assay, nuclear magnetic resonance
(NMR) spectral analysis, isothermal titration calorimetric (ITC)
assay, and thermal denaturation experiments, we show that (1) the
GQ structures do in fact exist in these RNA sequences, (2) the GQbinding ligands such as Braco-19 and TMPyP4 bind speciﬁcally to
these structures and stabilize them, and (3) treatment of ZIKVinfected cells with these ligands results in signiﬁcant reduction in
infectious virus production, as well as inhibition of viral genome
replication and viral protein production in a dose-dependent manner.
Thus, GQ-ligand binding strategy displayed in this study stands as a
proof of concept and appears promising toward the development of
potential antiviral agents against ZIKV infection.

RESULTS
ZIKV genome has potential GQ structures conserved across the
strains
Figure 1. G-quadruplex (GQ) structures are conserved in ZIKV genome
(A) Schematic diagram showing the location of the GQ sequences predicted in the
ZIKV genome. The seven ZGQ sequences used in the study are distributed in the NS
genes, namely, NS2, NS3, NS4B, and NS5, and one in the 30 UTR region. (B)
WebLogo representation of the newly predicted four ZGQ sequences showing
conservation of the nucleotides among different strains. The height of the letter
indicates the relative frequency of the particular nucleotides at that position,
therefore reflecting the conservation of that particular nucleotide.

the growth of cancer cells.21–23 These sequences also play signiﬁcant
role in neurodegenerative diseases like fragile X syndrome, Amyotrophic Lateral Sclerosis, and frontotemporal dementia.24,25 The search
of biologically important GQ sequences has been ramiﬁed in other
organisms as well, including yeast,26 bacteria,27–29 parasites,30 and viruses.15,16 Several viruses including ZIKV,31 human papillomaviruses
(HPV),32 herpes simplex virus (HSV),33 and human immunodeﬁciency virus (HIV)34 are reported to bear GQ-forming sequences in
their genome. Founded on this, the GQ-binding ligands such as
Braco-19 and core-extended naphthalene diimides are reported to
have a signiﬁcant antiviral effect on HIV replication.35,36 Another
potent GQ-binding ligand, TMPyP4, was found to stabilize the GQ
structure in the Ebola virus polymerase (L) gene, thereby repressing
its expression at the RNA transcription level.37 A similar effect of
TMPyP4 was also observed in the case of the core gene of hepatitis
C virus (HCV).38 These studies provide a framework for further
research on the potential use of GQ-binding and -stabilizing ligands
for antiviral strategies.15,16
In a recent report, Fleming et al.31 ﬁrst reported the presence of putative GQ-forming sequences in the ZIKV genome that are largely
conserved among the Flaviviridae family, although the functional
consequences of the presence of such structures were not examined
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Earlier reports suggest that Flaviviruses including the ZIKV contain
conserved GQ-forming sequences.31 By employing more stringent
criteria where the number of guanine repeat was kept R2 and the
loop length was restricted between 1 and 7, we identiﬁed four new
ZIKV GQs (ZGQs) conserved in the NS genes such as NS2, NS4B,
and NS5 genes of ZIKV genome in addition to the other ZGQs identiﬁed previously (Figure 1A).31 Importantly, the genome-wide mining
of 247 ZIKV isolates revealed that these new ZGQs are conserved
among >90% of the ZIKV strains (Figure 1B; Tables S1, S2, and
S9). As Figure 1B displays, the WebLogo representation of the newly
predicted four ZGQ sequences shows that the guanine residues
involved in the GQ formation are highly conserved among the
different evaluated strains and the residues present in the loop region
are mostly divergent. Because ZIKV is an RNA virus, it is prone to a
higher mutation rate,39 and thus, the conservation of these ZGQs
across the isolates suggests functional importance associated with
viral life cycle and pathogenesis. In addition, we have also identiﬁed
highly conserved ZGQ sequence motifs in the viral anti-genomic
(negative-sense) RNA (Figure S1; Table S3).
After identifying the ZGQ sequences in the positive-sense genomic
RNA, we conducted circular dichroism (CD) spectroscopy and nuclear magnetic resonance (NMR) spectroscopy studies to determine
whether they would form the GQ structures in vitro. It is well documented that these RNA GQ-forming sequences show less polymorphism in topology as compared to the DNA GQs and they are usually
observed to form parallel topology, with one reported exception, i.e.,
Spinach, as it forms the anti-parallel topology.17 Consistent with this
notion, we observed that the newly predicted ZGQs formed the signature pattern for parallel topology in the CD spectra, i.e., a negative
peak at 240 nm and a positive peak at 265 nm in the presence
of different cations (Figure 2A). Additionally, the 1H NMR spectra
showed distinct chemical shift signals between 10.5 and 12 ppm,
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Figure 2. Biophysical characterization of ZGQs
(A) CD spectra analysis of ZGQs showing parallel RNA
topology in the presence of cations, namely, K+, Na+, Li+,
and Mg2+. (B) 1H NMR spectra analysis of the ZGQs
showing the signature imino proton peaks in the predicted
four ZGQs, thus confirming the Hoogsteen bond formation in GQ structure.

which depict the characteristic peaks of the imino region embracing
the Hoogsteen base pairing in the GQ structures (Figure 2B). These
results are consistent with the formation of ZGQ structures within
the ZIKV RNA sequences examined here.
Interaction of potential ZGQs with GQ-binding ligand Braco-19
demonstrated by fluorescence-binding assay

Along with the advent of predicting and analyzing GQ structures, the
development of small-molecule ligands, which could speciﬁcally
target these GQ structures, have also been intensiﬁed. GQ-speciﬁc
molecules like Braco-19 and TMPyP4 are extensively used for targeting GQ structures in the telomere region,40–42 in viruses like in HIV35
and HSV.33 These particular molecules are immensely used to distinguish and characterize GQ forming sequences from the canonical
DNA or RNA sequences. Thus, we evaluated the interaction ability
of these GQ-speciﬁc ligands with the predicted ZGQs. We performed
ﬂuorescence-binding assays of Braco-19 with all the four newly predicted ZGQs along with the earlier reported GQs (ZNS3, ZNS5A,
ZNS5B, and Z3UTR).31 This assay is a simple optical assay that makes
use of the intrinsic ﬂuorescence property of the ligand molecule. Fluorescence-binding assay helps to determine the binding afﬁnity between two molecules (in our case, the GQ-speciﬁc ligand, Braco-19,
and the RNA) and obtain a quantitative value in the form of dissociation constant (KD).43 The binding efﬁciency between the ligand and
the biological molecules, i.e., RNA, is evaluated through the difference

between the ﬂuorescence intensity observed
before the addition of the RNA and after its
interaction with the ligand. The successful interaction results in either increase (enhancement)
or decrease in ﬂuorescence intensity (quenching). This change in ﬂuorescence (DF) is plotted
with respect to the concentration of RNA (GQs
or canonical) using global curve ﬁtting methods
to obtain the KD values for each interaction. The
respective KD value is used to analyze the binding afﬁnity of the ﬂuorescent molecule with each
nucleic acid. In the present study, all the ZGQs
showed higher binding afﬁnity (>100-fold
higher) for Braco-19 in comparison to the
duplex control RNA sequence (Figure 3; Table
S4). The variation in binding afﬁnity of different
ZGQs with Braco-19 is probably due to different
polymorphic structures formed by the GQ-sequences and so the ligand molecules bind with
the different RNA sequences with varying intensity. It should be noted that a higher afﬁnity of Braco-19 toward the
GQ sequences is attributed by the p-p interactions between the aromatic region of the ligand and the GQ-forming scaffolds of the ZGQs.
Moreover, Braco-19 contains two pyrrolidine rings, which contribute
to the cationic nature of the molecule and help to interact with the
anionic core of the GQ structures. All these properties contribute to
the mode of binding between the ligand and the biomolecule and
thereby can exhibit different binding modes, for example, groove
binding or end-stacking modes. In our study, all the sequences
were best ﬁtted in the two-mode binding model depicting more
than one site being present in the RNA sequences for the ligand binding. The KD1 values were higher in each case, conﬁrming preferential
binding mode and better afﬁnity of the ligand toward the ZGQ
sequences.
The higher binding affinity of Braco-19 with ZGQs confirmed by
ITC

ITC is regarded as the gold standard technique for determining the
thermodynamic properties of a bio-molecular interaction. Unlike
the ﬂuorescence-binding assay, it not only provides the binding constant values but also offers insight into the thermodynamic parameters including enthalpy changes, stoichiometry value, entropy
changes, and Gibbs free energy. Thus, we performed ITC studies using the ZGQs and Braco-19 to have better insight regarding the interaction proﬁle. Interestingly, the binding afﬁnity values between
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Figure 3. Fluorescence titration studies of Braco-19 with different ZGQ
RNAs
The solid, colored lines represent the plot for fitting the data obtained due to the
interactions of Braco-19 with the respective RNAs by two-mode binding. Table S4
lists the binding constant values (KD) obtained after fitting the plots.

Braco-19 and ZGQs were observed in mM scale, while with the control
duplex RNA, the value ranged in mM scale conﬁrming that the GQ
speciﬁc ligand, Braco-19 has a higher selectivity for the ZGQ-forming
structures over the non-GQ-forming sequences (Figure 4; Table S5).
ITC was also performed for the ZGQs with TMPyP4 and in similar
manner; TMPyP4 also showed a higher afﬁnity for the GQ sequences
(Figure S2; Table S7). In certain binding thermograms, for example in
Figures 4A–4D, we ﬁnd endothermic binding where the saturation
level is low, while the reactions turn exothermic at higher levels of
saturation. This implies that the stronger binding of the ligand to
the RNA is entropically driven while those that show weaker binding
are enthalpically directed.44
Thermal denaturation profile shows the stabilization of the
ZGQs by Braco-19

The thermal denaturation experiments illustrate the stability of the
GQ structures. The gradual increase in temperature leads to a change
in conformation of the nucleic acid structure due to disruption of the
bonds between the bases making it less stable.45 The higher melting
temperature (Tm) signiﬁes higher stability of the nucleic acid conformation. In our assays, when the ligand, Braco-19, was added in double
the molar concentration to that of the ZGQ RNA solution, we
observed a signiﬁcant increase in Tm values. Tm differences of
3.6 C to 13.1 C were noted for different ZGQs on interaction with
Braco-19 (Figure 5; Table S6). The ligand molecule interacts with
the GQ structures, thereby stabilizing them by forming non-covalent
bonds. On interaction with the ligand molecules, these GQ structures
become relatively more stable at higher temperature, which in turn
increases the melting temperature.
ZIKV growth is inhibited in vitro in the presence of GQ-binding
compounds Braco-19 and TMPyP4

The studies described above suggest that the ZIKV genome contains
GQ structures that can be stabilized through the binding of Braco-19,
as well as TMPyP4. To determine whether the presence of such structures and stabilizing them through binding with Braco-19 could
impact ZIKV growth in cultured cells, we performed experiments
to assess ZIKV growth in Vero cells in the presence of varying con-
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centrations of the drug. Vero cells infected with MR766 isolate of
ZIKV were treated with Braco-19 and infectious virus yield in the supernatants at various time points was measured by plaque assay. In
response to Braco-19 treatment, starting from 48 h post-infection,
the total infectious virus yield showed a signiﬁcant reduction in a
dose-dependent manner, at each of the time points examined (Figure 6A). Strikingly, at 100 mM of Braco-19 (cell viability was greater
than 85% (Figure 6C) at 100 mM concentration), inhibition of virus
growth was most signiﬁcant (>80-fold, p % 0.0001) at 96 hpi
compared to the untreated control (Figure 6A). We also investigated
the effect of TMPyP4, another GQ-binding molecule on virus yield in
a similar assay. Our results showed that TMPyP4 also inhibited virus
growth signiﬁcantly (Figure 6B). At a concentration of 10 mM, at
which cell viability was over 80% (Figure 6C), the infectious virus
yield in the supernatants at 72 hpi and 96 hpi was reduced nearly
120-fold and 170-fold, respectively, compared to the untreated control (Figure 6B). However, at 100 mM concentration, the infectious virus yield in the supernatant was below the limit of detection at any of
the time points studied (Figure 6B), even though the cell viability was
nearly 40% (Figure 6C). Overall, these results suggest that GQ-binding compounds Braco-19 and TMPyP4 inhibit ZIKV growth in vitro.
To determine whether the lower levels of infectious virus in the culture supernatants in the presence of the Braco-19 or TMPyP4 were
a result of increased accumulation of cell-associated infectious virus,
we quantitated the amount of virus present in the cells. As can be seen
in Figure 6D, on average, cell-associated virus represented about
17-fold less than the virus released in the supernatants of infected cells
under no-drug treatment condition at 72 hpi. In the presence of
100 mM Braco-19 or 10 mM TMPyP4, cell-associated virus represented approximately 14- to 15-fold less than that in the corresponding supernatants. Importantly, the cell-associated virus in drugtreated cells were signiﬁcantly lower than those in untreated cells
(Figure 6D). These results show that both Braco-19 and TMPyP4
inhibit infectious ZIKV progeny production.
Inhibition of viral protein synthesis and genome replication in
infected cells treated with Braco-19 and TMPyP4

Since Braco-19 and TMPyP4 treatment reduced infectious ZIKV
yield, we next sought to ﬁnd out whether this is due to lower viral protein expression in infected cells. We examined the E protein expression levels in virus-infected cells in the presence of Braco-19 or
TMPyP4. Since the ZIKV genome is translated into a single large polyprotein, which is processed to yield 10 different proteins including
the E protein, we picked the E protein as an indicator viral protein
production. Vero cells, infected with MR766 ZIKV, were treated
with varying concentrations of Braco-19 or TMPyP4 immediately after infection. Cell lysates were prepared from the infected cells at 48 or
96 hpi and analyzed for E protein levels by western blot, which
showed a marked reduction in E protein expression with increasing
concentrations of Braco-19 at both 48 hpi and 96 hpi (Figures 7A
and 7B). The reduction of E protein levels was more pronounced at
100 mM Braco-19 and at 96 hpi. In response to TMPyP4 treatment,
E protein expression showed observable reduction over time (Figure 7C). Surprisingly, the electrophoretic mobility of the E protein
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Figure 4. Braco-19 has a higher binding affinity and
thermal profile for ZGQs
Isothermal titration calorimetric experiment showing the
binding affinity between the ZGQ RNAs and Braco-19
(A: ZGQ1, B: ZGQ2, C: ZGQ3, D: ZGQ4, E: ZNS3, F:
ZNS5A, G: ZNS5B, H: Z3UTR and I: Duplex RNA-Control). The top panel represents the power in mcal unit
versus time in s while the bottom panel depicts the
thermogram of the integrated peak intensities plotted
against the molar ratio. The binding constant values for all
the ZGQ RNAs along with the control RNA are listed in
Table S5.

ZIKV-speciﬁc primers and probes to determine
the copy numbers of the viral positive-sense
genome. In these experiments, we used
100 mM Braco-19 because this concentration exhibited maximum inhibition without adversely
affecting cell viability and 10 mM TMPyP4
because higher concentration of TMPyP4 was
found to reduce cell viability substantially (Figure 6C). Results from the experiment showed
that ZIKV genome copies were signiﬁcantly
lower in cells treated with Braco-19 or TMPyP4
at both 72 and 96 hpi (Figure 7E), suggesting
that these GQ-binding molecules inhibit ZIKV
genome replication in infected cells. Overall,
from these studies we conclude that GQ-binding
drugs inhibit both viral genome replication, as
well as translation.

DISCUSSION

was demonstrably altered at 48 hpi time point (Figure 7C), with
increasing dose of TMPyP4 resulting in increased molecular mass
of the E protein. Interestingly at 96 hpi, the reduced electrophoretic
mobility of E was only observed with 100 mM TMPyP4 (lane 5, Figure 7D) and was also less pronounced. The reason for the observed
electrophoretic mobility shift in E protein in the presence of TMPyP4
is unclear at this time but it is possible that metabolic byproducts of
TMPyP4, known to be generated in cells could bind to the E protein in
a time- and concentration-dependent manner to reduce the mobility
of the E protein (see Discussion for further details). Nevertheless, our
results suggest that both Braco-19 and TMPyP4 inhibit viral protein
expression in infected cells.
We next sought to determine whether intracellular replication of the
ZIKV genome is negatively affected by the GQ-binding ligands. Vero
cells, infected with ZIKV MR766, were treated with Braco-19,
TMPyP4, or left untreated and total RNA from the cells was extracted
at 72 and 96 hpi. Total RNA was subjected to qRT-PCR with

Due to the unavailability of commercial vaccines
or antiviral drugs, control and mitigation strategies for ZIKV infection remain a huge challenge
to date. The unpredictable nature of ZIKV outbreaks and the global prevalence of its vector have further worsened
the situation. Although attempts to repurpose the drugs like Sofosbuvir,46 Niclosamide,47 and Galidesivir48 have shown pronounced antiZika activity, these drugs also come with certain shortcomings such as
poor bioavailability, poor liberation, and improper mode of administration. If infected during pregnancy, ZIKV can cause detrimental effects on the fetus and eventually on the newborn. Prognosis of
newborn babies infected with ZIKV is unfavorable and infections
could lead to permanent congenital defects. Thus, utmost precaution
and precision should be taken while strategizing therapeutic countermeasures against ZIKV infection.
In recent years, GQ structures, which are non-canonical nucleic acid
secondary structures, are being discovered in almost all organisms
including many viral genomes and thus have been considered as
potential targets for antiviral strategies.16 ZIKV and other Flaviviruses
are earlier reported to possess conserved GQ structures.31 By expanding the analysis to all the available ZIKV genome sequences published
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Figure 5. Thermal denaturation analysis showing stabilization ZGQs in the presence of Braco-19
The increase in Tm depicts the stable interaction of the ZGQs with Braco-19 (A: ZGQ1, B: ZGQ2, C: ZGQ3, D: ZGQ4, E: ZNS3, F: ZNS5A, G: ZNS5B and H: Z3UTR). The Tm
difference (noted in the left bottom corner) is significant for all the ZGQ RNAs (also see Table S6).

in the NCBI Genome database and employing an in-house algorithm,49
we were able to predict four additional highly conserved GQ structures
in ZIKV. Some GQ-forming sequences were also found to be conserved
in the anti-genomic strand of the ZIKV (replication intermediate; Figure S1; Table S3). However, further studies will be required to validate
whether they actually form GQs. The current study mainly focuses on
the GQ structures formed in the genomic RNA (positive polarity) of the
ZIKV. The observation that these GQ structures are highly conserved
suggested to us that they may play a speciﬁc role in the biology and/or
pathogenesis of the virus. Two of the GQs were found to be located in
the coding region of NS5 gene, i.e., the RNA-dependent RNA polymerase coding gene, while the other two were present in the NS2 and NS4B
gene. These GQs were characterized by CD and NMR spectra analysis
and were found to form parallel GQ structures. Moreover, it has been
previously shown that RNA GQ structures are more stable compared to
their DNA counterparts due to the presence of the 20 hydroxyl group in
the ribose sugar. Following CD and NMR spectra studies, we evaluated
whether these GQ structures would interact with the known GQ-binding ligands. GQ-binding ligands such as Braco-19, TMPyP4, etc. have
been widely studied to measure the stability of the GQ structures and
are presently being explored as an antiviral strategy. The ligands bear
certain characteristics like basic aromatic rings, electron-deﬁcient
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cationic core, and positively charged side chains, which facilitate the
efﬁcient interaction of these ligands with the GQ secondary structures.50 The mode of interaction of these ligands may be through
end-stacking, groove binding, or interaction with the backbone or
loop sequences. The molecules ﬁt themselves within these GQ structures and bind through various non-covalent bonds thus stabilizing
the structure. Further biophysical studies including the ﬂuorescence
titration assay, ITC, and thermal denaturation assay conclusively
demonstrated that the Braco-19 and TMPyP4 bind selectively and preferentially to the GQ-forming sequences in comparison to the non-GQ
linear RNA sequences. Our studies unequivocally demonstrated the existence and formation of GQ structures in the genome of ZIKV.
We reasoned that the binding of the Braco-19 or TMPyP4 could potentially impact the function(s) of the viral RNA containing the GQ structures. Our in vitro studies in cells infected with ZIKV and treated with
Braco-19 or TMPyP4 suggested that both of these compounds inhibit
the activities of the RNA template. Viral protein synthesis was substantially reduced in a dose-dependent manner as evidenced by the reduced
levels of the E protein in the cells compared to control cells. Additionally, it is possible that binding of these compounds to the GQ structures
inhibited the movement of the viral RNA polymerase, resulting in
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Figure 6. Inhibition of ZIKV growth in cells treated
with Braco-19 and TMPyP4
(A and B) Vero cells infected with ZIKV at an MOI of 1 were
incubated in medium containing 0 (untreated), 1 mM,
10 mM, and 100 mM concentrations of Braco-19 (A) or
TMPyP4 (B). Aliquots of culture supernatants were
collected at various times (h post-infection, hpi) and infectious virus titers were determined by plaque assay. The
graphs show mean values of virus titers, with error bars
representing standard deviations from the results of four
independent experiments. Two-way ANOVA was used to
determine significant differences in virus titers between
untreated and drug-treated samples. LOD, the limit of
detection. # represent values below LOD. ****p % 0.0001;
***p % 0.001; ns, nonsignificant. (C) Cell viability in the
presence of Braco-19 or TMPyP4. Vero cells were
exposed to 0, 1, 10, and 100 mM Braco-19 or TMPyP4 for
4 days and percentage of viable of cells was measured.
Mean values from three independent experiments with
error bars representing standard deviations are shown. (D)
Vero cells were infected with ZIKV at an MOI of 1 and
treated with 100 mM Braco-19 or 10 mM TMPyP4 for
72 hpi. Infectious virus in the supernatants and cells were
quantitated by plaque assay. The graphs show mean
values of virus titers, with error bars representing standard
deviations from the results of three independent experiments. Two-way ANOVA was used to determine significant differences in virus titers between untreated and
drug-treated samples. ***p % 0.001; **p % 0.01.

overall reduction of viral RNA copy numbers as we have observed in
our experiments. Although our studies revealed the existence of multiple functional GQ structures in the viral genome, it would be interesting
to examine whether a particular GQ structure functions more prominently than the other structures. In this regard, further studies are being
planned to identify a speciﬁc contribution of these GQ structures in inhibiting viral genome replication and translation.
Examination of E protein in ZIKV-infected cells treated with
TMPyP4 revealed slower migrating forms of the protein (Figures
7C and 7D). It appears to be speciﬁc for E protein since such mobility
differences were not observed with another viral protein, the NS1 protein (data not shown). The molecular basis for the differences in
mobility of E compared to that in TMPyP4-untreated cells is not clear
at this time. However, it is known that TMPyP4 becomes metabolized51 in cells through oxidation by hemeoxygenase enzymes
(HO-1 and HO-2) to produce 4-formyl-1-methylpyridinium (4FMP) and 4-carboxyl-1-methylpyridinium (4C-MP). Since these
metabolites can bind to certain cellular proteins such as acetylcholinesterase,51 it is possible that 4F-MP and/or 4C-MP bind speciﬁcally to
the viral E protein in a time- and concentration-dependent manner to
reduce its mobility. Although our results are consistent with such an
interpretation, further research is needed to determine the molecular
basis of the observed mobility shift in the E protein.
Taken together, our studies provide the ﬁrst evidence that highly
conserved GQ structures present in ZIKV genome and the ligands

that bind and stabilize these GQ structures can potently inhibit
ZIKV growth, genome replication, and viral protein expression in
cultured cells. However, the two ligands evaluated here are the
most common GQ-speciﬁc ligands used regularly to characterize
these secondary structures and not highly speciﬁc to the particular
ZIKV GQs. Moreover, the toxicity and bioavailability of these ligands
pose a hindrance for their potential use as antiviral drugs. Though this
piece of research stands as a proof of concept for using GQ-binding
ligands as anti-ZIKV drugs, development of sequence-speciﬁc ligands
needs further research.16 Moreover, the availability of ligands that can
potentially target ZIKV GQ sequences and that have the ability to
distinguish them from the host GQs can address the problem of
off-target effects of the ligands. Thus, these results open the possibility
for understanding the role of GQ structures in ZIKV life cycle and
pathogenesis, as well as for use of these structures as targets for development of innovative and efﬁcacious antiviral strategies.

MATERIALS AND METHODS
Oligonucleotides and reagents

Small-molecule ligands, namely Braco-19 and TMPyP4, were purchased from Sigma Aldrich Chemicals, dissolved in water or DMSO,
respectively, for preparation of stock solutions, and stored at 4 C until
further use. Other reagents and chemicals including KCl, KH2PO4,
K2HPO4, DMSO, and D2O were procured from Sigma Aldrich Chemicals or HiMedia Laboratories. The DNA oligonucleotides and the
RNA oligonucleotides used in the studies were obtained from Sigma
Aldrich Chemicals and IDT Technologies, respectively (Table S8).
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CD melting analysis

J-815 spectropolarimeter (JASCO) attached with a Peltier junction
temperature controller was used to perform the CD experiment.
With continuous supply of nitrogen gas, the required temperature
was maintained to avoid condensation of water along the cuvette.
20 mM RNA sample dissolved in Tris buffer (10 mM, pH = 7.4, supplemented with the required cation) was used for the CD spectra analysis. For the CD spectra analysis, the wavelength range of 220–320 nm
was scanned at the speed of 20 nm/min while the thermal denaturation experiments were carried out at 265 nm at a temperature
range of 25 C to 98 C. The ligand was added gradually in increasing
concentration to the ZGQ RNA solution. The experiments were done
in triplicate and data were obtained and normalized by buffer subtraction. Following this, the result was plotted using SigmaPlot 12.0 software (Systat Software, Chicago, IL, USA).
NMR spectroscopy

The NMR experiment was carried on in the AVANCE 400 MHz
(BioSpin International AG, Switzerland) spectrometer supported
with the 5 mm broadband inverse (BBI) probe as reported earlier.28
Figure 7. Braco-19 and TMPyP4 inhibit viral protein synthesis and genome
replication
(A–D) Vero cells were either mock-infected (M) or infected with ZIKV at an MOI of 1
and subsequently incubated in medium containing 0, 1 mM, 10 mM, and 100 mM
concentrations of Braco-19 (A and B) or TMPyP4 (C and D). Cell extracts were
prepared at 48 hpi (A and C) or 96 hpi (B and D) and 20 mg of proteins from each
sample were analyzed by SDS-PAGE and western blotting with 4G2 antibody to
detect viral E protein. Levels of actin detected in the blots using anti-actin antibody
served as the loading control. Molecular mass markers (in kDa) are shown on the
left. Representative data are shown in each panel. (E) Levels of viral genome in the
presence of Braco-19 or TMPyP4. Vero cells infected as above were and incubated
in medium without drug (untreated) or containing 100 mM Braco-19 or 10 mM
TMPyP4. Viral genome copies in the cells at 72 and 96 hpi were quantitated and
expressed as copies per mg of total cellular RNA from the cells. The graphs show
mean values of genome copy numbers with error bars representing standard deviations from the results of three independent experiments. Two-way ANOVA was
used to determine significant differences between untreated and drug-treated
samples. ****p % 0.0001; ***p % 0.001.

Prediction of putative GQ-forming sequences from the ZIKV
genome

A total of 247 complete genome sequences of ZIKV were retrieved
from the NCBI Genome database (https://www.ncbi.nlm.nih.gov/
genomes). The FASTA sequences of the ZIKV genomes were then
used for the prediction of the putative GQ-forming sequences with
the help of our in-house GQ prediction tool.48 The search was based
on the following algorithm:
GR2 N17 GR2 N17 GR2 N17 GR2
where G corresponds to guanine and N corresponds to any base
including guanine. Though the ZIKV is a positive-sense RNA virus,
we also sought to ﬁnd the probable GQ sequences in the anti-sense
strand of the viral genome. Further, the consensus sequences for
each of the ZGQs studied were generated using the WebLogo
software.52
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Fluorescence-binding assay

The ﬂuorescence titration experiment was performed using the Synergy H1 multi-mode plate reader. 2 nM of ligand was added to each of
the 12 wells of a 96-well plate and gradually the target RNA was
titrated in each of the wells (0–10 mM). Precisely, the highest concentration of RNA, i.e., 10 mM, was added to ﬁrst well, followed by dilution in the subsequent well; for example, the second well then
contained 5 mM, third well contained 2.5 mM, and so on until the eleventh well while no RNA was added in the last well (twelfth well)
serving as blank. The enhancement in emission ﬂuorescence was
observed at speciﬁc excitation of the ligand molecule (lex = 360 nm
and lem = 440 nm for Braco-19) on addition of RNA and the change
in emission ﬂuorescence (DF) for all datasets was normalized to the
last well (containing no RNA). The two-site saturation using global
curve ﬁtting was used to extrapolate the curve between DF and
concentration of RNA (mM) using SigmaPlot 12.5 software (Systat
Software, Chicago, IL, USA) according to the following equation
that accounts for two receptor binding sites with two different afﬁnities, KD1 and KD2:
y=

Bmax1  absðxÞ Bmax1  absðxÞ
+
KD 1  absðxÞ
KD 2  absðxÞ

where Bmax is the maximum number of binding sites and KD is the
dissociation equilibrium constant. Each binding study was performed
in duplicate at room temperature (RT) and duplex RNA was used as
the control.

ITC experiment

The ITC experiments were performed using the MicroCal iTC200
isothermal titration calorimeter (GE Healthcare) instrument. The
RNA sample was prepared in potassium phosphate buffer and loaded
in the cell while the ligand was loaded in the syringe. A total of 21
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injections were performed where each injection delivered 1.78 mL of
ligand and was of 3.56 s duration with a gap of 120 s between two.
An initial injection of 0.4 mL having 60 s initial equilibrium delays
was maintained during each experiment. Throughout the experimental
period, 25 C temperature and 750 rpm speed were sustained. The data
obtained were ﬁtted to the two-site binding model and analyzed using
the Origin scientiﬁc software version 7 (Microcal Software).

albumin (for phosphorylated proteins) in Tris-buffered saline containing 0.2% Tween 20 (TBS-T) and incubated with the appropriate
primary antibodies (dilution: 1:5,000 for b-actin and 1:1,000 for all
others) at 4 C overnight. Membranes were washed with TBS-T and
incubated with appropriate HRP-conjugated secondary antibodies
(dilution: 1:5,000) at RT for 2 h. Bands were detected using enhanced
chemiluminescence (ECL) western blotting substrate using a BioRad
imager.

Cells and viruses

Vero (Cercopithecus aethiops, CCL-81) cells were obtained from
American Type Culture Collection (ATCC). The cells were grown
and maintained in Dulbecco’s modiﬁed Eagle’s medium (DMEM)
containing 10% heat-inactivated fetal bovine serum (FBS) and penicillin/streptomycin (PS) in humidiﬁed chamber with 5% CO2 at
37 C. The infectious clone-derived MR766 strain of ZIKV53 generated in our laboratory was used in this study. For determination of virus growth in the presence of Braco-19 or TMPyP4, Vero cells were
infected with the virus at a multiplicity of infection (MOI) of 1 plaque-forming unit per cell (PFU/cell). Following adsorption at 37 C
for 1 h, the inoculum was removed and replaced with virus growth
medium as described before53,54 containing appropriate concentrations of Braco-19 or TMPyP4. Infected cells were incubated at 37 C
and small aliquots of infected cell culture supernatants were collected
at various hpi, clariﬁed, and stored at 80 C for virus titration at a
later time. To determine the amount of cell-associated infectious virus, after collecting culture supernatants, we subjected the cells to
two cycles of freeze-thaw at 80 C in the presence of the same volume of growth medium followed by centrifugation at 17,000  g
for 10 min at 4 C. The clariﬁed supernatants were then used to quantify the cell-associated virus. Virus quantitation was performed by
plaque assay on Vero cells as described previously.53

Total RNA from infected cells at 72 or 96 hpi were isolated using TRIzol RNA isolation reagent (Thermo Fisher Scientiﬁc) and viral
genomic copy numbers were determined using speciﬁc probes and
primers as described in detail previously53 and expressed as log10
copies per mg of total cellular RNA. The forward primer (50 -GTC
GTTGCCCAACACAAG-30 ) and the reverse primer (50 -CCAC
TAATGTTCTTTTGCAGAC-30 ) along with the ﬂuorescent probe
50 -/56-FAM (50 -6-carboxyﬂuorescein)/AGCCTACCT/ZEN/TGACA
AGCAATCAGACACTCAA/3IABkFQ (30 -Iowa black ﬂuorescent
quencher)/-30 were used to determine the standard curve. The realtime PCR assays involved two steps. The ﬁrst step included the
cDNA synthesis from the viral RNA using the SuperScript II (Thermo
Fisher Scientiﬁc, Waltham, MA, USA). The synthesized cDNAs were
then used as templates in the qPCR. The qPCR cycling conditions
used were as follows: initial denaturation at 95 C for 10 mins; 35 cycles of 95 C for 30 s, 55.3 C for 30 s, and 72 C for 30 s; and a melt
curve from 65 C to 95 C with 0.5 C increments for 5 s. The reactions
were run in CFX Connect instrument (Bio-Rad, Hercules, CA, USA).
Viral-genome copy numbers were determined in parallel reactions
using RNA samples in duplicate and expressed as copy numbers
per mg of total cellular RNA.

Western blotting for E protein

Determination of cell viability by flow cytometry

ZIKV E protein was detected in infected cells treated without or with
the GQ-binding ligands at appropriate concentrations. Cell extracts
were prepared, and the viral E protein was detected by western blotting as described before.53 Anti-ZIKV E protein antibody was obtained from Genetex (Cat. # GTX1333325) and goat anti-rabbit
immunoglobulin G (IgG)-horseradish peroxidase (HRP)-conjugated
(Cat. # A6154) was procured from Sigma Aldrich. Mock-infected or
virus-infected cells were washed with cold PBS, trypsinized, and harvested at 500  g for 5 min at 4 C. The cell pellet was resuspended in
radioimmunoprecipitation assay (RIPA) buffer (25 mM Tris-HCl,
pH 7.6, 150 mM NaCl, 1% Triton X-100, 1% sodium deoxycholate,
0.1% SDS) supplemented with the protease and phosphatase inhibitor
cocktail and incubated on ice for 15 min with intermittent vortexing
after which the lysates were clariﬁed by centrifugation at 10,000  g
for 5 min, 4 C. Total protein quantiﬁcation was done using the bicinchoninic acid (BCA) assay kit. 20 mg of total protein was separated by
electrophoresis on a required percentage of polyacrylamide gel
(PAGE) containing sodium dodecyl sulfate (SDS). The separated
proteins were transferred onto polyvinylidene ﬂuoride (PVDF) membranes using a Bio-Rad semi-dry transfer system. Non-speciﬁc protein binding was blocked with 5% non-fat milk or with bovine serum

Cell viability was determined by simultaneous determination of propidium iodide (PI, 1 mg/mL, Sigma Aldrich, P4170) uptake as a
marker of plasma membrane integrity loss and changes in the forward
scatter properties of the cell (cell size) using ﬂow cytometry (ﬂuorescence-activated cell sorting [FACS]). Flow cytometry and data analysis were performed as described previously.55

Quantitative real-time PCR

Statistical analysis

Data were analyzed using GraphPad Prism software version 6.0. Twoway ANOVA was used to determine signiﬁcant differences between
untreated and drug-treated samples for viral loads (RNA copies, infectious titer). Data were represented as either mean ± SEM or
mean ± SD.
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